Stockscreener 앱 받기
23.70
3.00%
0.69
시간 외 거래:
23.70
전일 마감가:
$23.01
열려 있는:
$23.06
하루 거래량:
1.05M
Relative Volume:
0.89
시가총액:
$2.97B
수익:
$247.00M
순이익/손실:
$-353.00M
주가수익비율:
-7.1812
EPS:
-3.3003
순현금흐름:
$-484.00M
1주 성능:
+4.64%
1개월 성능:
+7.87%
6개월 성능:
+40.24%
1년 성능:
+195.88%
1일 변동 폭
$22.61
$23.87
1주일 범위
$22.07
$23.87
52주 변동 폭
$7.06
$26.40
Arcus Biosciences Inc Stock (RCUS) Company Profile
명칭
Arcus Biosciences Inc
전화
(510) 694-6200
주소
3928 POINT EDEN WAY, HAYWARD, CA
Compare RCUS vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RCUS
Arcus Biosciences Inc
|
23.70 | 2.88B | 247.00M | -353.00M | -484.00M | -3.3003 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Arcus Biosciences Inc Stock (RCUS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-12 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2026-01-13 | 업그레이드 | Goldman | Neutral → Buy |
| 2026-01-08 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2025-02-26 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2024-10-21 | 개시 | H.C. Wainwright | Neutral |
| 2024-10-08 | 개시 | Wells Fargo | Overweight |
| 2022-11-18 | 개시 | BofA Securities | Neutral |
| 2022-10-11 | 개시 | Morgan Stanley | Overweight |
| 2021-10-15 | 재개 | BTIG Research | Buy |
| 2020-11-24 | 개시 | Berenberg | Buy |
| 2020-11-23 | 개시 | Evercore ISI | Outperform |
| 2020-04-03 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-03-04 | 개시 | Barclays | Overweight |
| 2019-11-12 | 개시 | SunTrust | Buy |
| 2019-09-27 | 개시 | Mizuho | Buy |
| 2019-05-24 | 재개 | Citigroup | Buy |
| 2018-10-09 | 개시 | Wedbush | Outperform |
| 2018-04-09 | 개시 | Citigroup | Buy |
| 2018-04-09 | 개시 | Goldman | Neutral |
| 2018-04-09 | 개시 | Leerink Partners | Outperform |
모두보기
Arcus Biosciences Inc 주식(RCUS)의 최신 뉴스
RSI Check: What is Arcus Biosciences Incs valuation compared to sectorWeekly Trade Review & Fast Exit and Entry Strategy Plans - baoquankhu1.vn
Risks Report: Whats Arcus Biosciences Incs historical returnMarket Movement Recap & High Return Trade Guides - baoquankhu1.vn
Published on: 2026-04-13 14:48:40 - baoquankhu1.vn
Discipline and Rules-Based Execution in RCUS Response - Stock Traders Daily
Arcus Biosciences, Inc. Common Stock (NY: RCUS - FinancialContent
New Arcus hire gets 7,850 stock options at $22.65 plus 3,950 RSUs - Stock Titan
[144] Arcus Biosciences, Inc. SEC Filing - Stock Titan
Sell Signal: Can Arcus Biosciences Inc withstand a market correctionVolume Spike & Weekly Top Performers Watchlists - baoquankhu1.vn
Pharma News: Can Arcus Biosciences Inc keep up with sector leadersQuarterly Investment Review & Community Consensus Trade Signals - baoquankhu1.vn
Citigroup Maintains Arcus Biosciences (RCUS) Buy Recommendation - MSN
RCUS Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
RCUS Technical Analysis & Stock Price Forecast - Intellectia AI
Arcus Biosciences, Inc. (RCUS) Stock forecasts - Yahoo Finance UK
RCUS: Wedbush Raises Price Target for Arcus Biosciences | RCUS S - GuruFocus
Arcus Biosciences (NYSE:RCUS) Trading 5.4% Higher Following Analyst Upgrade - MarketBeat
Arcus Biosciences (NYSE:RCUS) Price Target Raised to $41.00 - MarketBeat
Gainers Report: Will Arcus Biosciences Inc stock benefit from M A2026 Breakouts & Risk Controlled Stock Pick Alerts - baoquankhu1.vn
Arcus Biosciences, Inc. (RCUS) Stock Forecasts - Yahoo Finance
Behavioral Patterns of RCUS and Institutional Flows - Stock Traders Daily
Insider Trends: Is Arcus Biosciences Inc still a buy after recent gains2026 Retail Activity & Real-Time Volume Analysis Alerts - baoquankhu1.vn
RCUS Price History for Arcus Biosciences Stock - Barchart.com
Arcus Biosciences (RCUS) Vanguard shows 0 shares after Jan 12, 2026 realignment - Stock Titan
Arcus Biosciences (NYSE:RCUS) Upgraded at Truist Financial - MarketBeat
Arcus Biosciences, Inc. (NYSE:RCUS) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Arcus Executives Offload Shares Amid Surge in Hiring—A "Pump and Dump" Warning Sign for RCUS - Bitget
Two new hires get Arcus stock awards priced at $21.41 a share - Stock Titan
Gilead Sciences Inc and Arcus Biosciences Inc Post ARC-7 Plenary Q&A Transcript - GuruFocus
Arcus Biosciences, Inc. Files Form 8-K with SEC for Common Stock Listed on NYSE (RCUS) - Minichart
Arcus Biosciences, Inc. Announces Resignation of Jennifer Jarrett as Chief Operating Officer, Effective March 30, 2026 - marketscreener.com
Arcus Biosciences Announces COO Resignation and Transition Plan - TipRanks
Arcus Biosciences chief operating officer Jennifer Jarrett to resign March 30 - Investing.com Australia
Arcus Biosciences' Jennifer Jarrett to Resign as COO, Effective March 30, 2026 - TradingView
Arcus Biosciences chief operating officer Jennifer Jarrett to resign March 30 By Investing.com - Investing.com South Africa
Arcus Biosciences COO Jennifer Jarrett to resign March 30 - StreetInsider
COO Jennifer Jarrett to exit Arcus Biosciences (RCUS), stay on as advisor - Stock Titan
Aug Setups: Can Arcus Biosciences Inc stock double in the next year2026 Earnings & Real-Time Buy Signal Alerts - baoquankhu1.vn
Hudson Bay Capital Management LP Has $4.62 Million Stake in Arcus Biosciences, Inc. $RCUS - MarketBeat
RCUS PE Ratio & Valuation, Is RCUS Overvalued - Intellectia AI
(RCUS) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Arcus Biosciences, Inc. (RCUS) Stock Price History & Data - Traders Union
B of A Securities Maintains Arcus Biosciences (RCUS) Neutral Recommendation - MSN
Arcus Biosciences, Inc. $RCUS Shares Bought by Decheng Capital LLC - MarketBeat
Here’s what analysts think about Arcus Biosciences (RCUS) - MSN
WINTON GROUP Ltd Purchases Shares of 92,229 Arcus Biosciences, Inc. $RCUS - MarketBeat
Why Arcus Biosciences (RCUS) Is Up 9.5% After New Casdatifan Data And Pipeline Expansion - simplywall.st
Arcus Biosciences (RCUS) Valuation After Casdatifan Kidney Cancer Data Pipeline Update And Earnings - Sahm
How (RCUS) Movements Inform Risk Allocation Models - Stock Traders Daily
New Arcus Biosciences hires receive stock options at $23.43 - Stock Titan
Arcus Biosciences at Leerink Conference: Casdatifan’s Promising Data By Investing.com - Investing.com Canada
RCUS: Casdatifan delivers higher efficacy and durable responses in RCC, with strong upcoming trial data - TradingView
Is Arcus Biosciences Inc still a buy after recent gainsWeekly Trading Summary & Comprehensive Market Scan Insights - baoquankhu1.vn
Arcus Biosciences Inc (RCUS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.69%
0.25%
자본화:
|
볼륨(24시간):